Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Clinical trial NCT03850574 · RECRUITING

Trial details

NCT number: NCT03850574
Sponsor: Aptose Biosciences Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Leukemia, Myeloid, Acute Refractory AML Relapsed Adult AML Myelodysplastic Syndrome With Excess Blasts-2 Chronic Myelomonocytic Leukemia

Start date: 2019-03-11
Primary completion: 2026-11-01
Enrollment: 240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.